{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T06:09:34Z","timestamp":1668492574942},"reference-count":35,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,9,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Interleukin-27 (IL-27), which belongs to IL-12 family, influences the function of T cells (Tregs) through regulating the expression, and function of forkhead box P3 (FoxP3). In this study, we detected the IL-27 serum levels in 59 myasthenia gravis (MG) patients and 35 healthy controls (HCs). Among them, 32 MG patients received immunoglobulin intravenous (IVIG) injections (0.4\u2009g\/kg per day for 5 consecutive days). IL-27 levels were collected before and after the treatments and subjected to a comparative study. Finally, we assessed the correlations of IL-27 levels with the clinical characteristics of MG. As a result, serum IL-27 levels were significantly higher in MG patients than those in the HCs. Meanwhile, significant reduction was detected after the IVIG treatment. IL-27 levels positively correlated with both MG activities of daily living and quantitative MG score. IL-27 may participate in the pathogenesis of MG and can be used as an early marker for the diagnosis and prognosis of MG. In addition, IL-27 can be used as a target for MG treatment through the regulation of specific immune signaling and maintaining immune homeostasis.<\/jats:p>","DOI":"10.1515\/tnsci-2020-0134","type":"journal-article","created":{"date-parts":[[2020,9,15]],"date-time":"2020-09-15T03:46:45Z","timestamp":1600141605000},"page":"302-308","source":"Crossref","is-referenced-by-count":0,"title":["Interleukin-27 levels in patients with myasthenia gravis"],"prefix":"10.1515","volume":"11","author":[{"given":"Xiao-Jiao","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Neurology, Tianjin Medical University General Hospital Airport Hospital , Tianjin , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin-Jie","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tianjin Medical University General Hospital Airport Hospital , Tianjin , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Yi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tianjin Medical University General Hospital Airport Hospital , Tianjin , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Min","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tianjin Medical University General Hospital Airport Hospital , Tianjin , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tianjin Medical University General Hospital Airport Hospital , Tianjin , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Qi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tianjin Medical University General Hospital Airport Hospital , Tianjin , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tianjin Medical University General Hospital Airport Hospital , Tianjin , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Da-Qi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tianjin Medical University General Hospital Airport Hospital , Tianjin , China"},{"name":"Department of Neurology, First Affiliated Hospital of Hainan Medical University , Haikou , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tianjin Medical University General Hospital Airport Hospital , Tianjin , China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2020,9,9]]},"reference":[{"key":"2022111412290861367_j_tnsci-2020-0134_ref_001","doi-asserted-by":"crossref","unstructured":"Andrews C, McLean MH, Durum SK. Interleukin-27 as a novel therapy for inflammatory bowel disease: a critical review of the literature. Inflamm Bowel Dis. 2016;22:2255\u201364.","DOI":"10.1097\/MIB.0000000000000818"},{"key":"2022111412290861367_j_tnsci-2020-0134_ref_002","doi-asserted-by":"crossref","unstructured":"Danikowski KM, Jayaraman S, Prabhakar BS. Regulatory T cells in multiple sclerosis and myasthenia gravis. J Neuroinflamm. 2017;14:117.","DOI":"10.1186\/s12974-017-0892-8"},{"key":"2022111412290861367_j_tnsci-2020-0134_ref_003","doi-asserted-by":"crossref","unstructured":"Roncarolo MG, Gregori S, Battaglia M, Bacchetta R, Fleischhauer K, Levings MK. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev. 2006;212:28\u201350.","DOI":"10.1111\/j.0105-2896.2006.00420.x"},{"key":"2022111412290861367_j_tnsci-2020-0134_ref_004","doi-asserted-by":"crossref","unstructured":"Yang G, Yang X, Zhang J, Li G, Zheng D, Peng A, et al. Transcriptional repressor Blimp1 regulates follicular regulatory T-cell homeostasis and function. Immunology. 2018;153:105\u201317.","DOI":"10.1111\/imm.12815"},{"key":"2022111412290861367_j_tnsci-2020-0134_ref_005","doi-asserted-by":"crossref","unstructured":"Zhao DM, Thornton AM, DiPaolo RJ, Shevach EM. Activated CD4+CD25+ T cells selectively kill B lymphocytes. Blood. 2006;107:3925\u201332.","DOI":"10.1182\/blood-2005-11-4502"},{"key":"2022111412290861367_j_tnsci-2020-0134_ref_006","doi-asserted-by":"crossref","unstructured":"Wen Y, Yang B, Lu J, Zhang J, Yang H, Li J. Imbalance of circulating CD4(+) CXCR5(+) FOXP3(+) Tfr-like cells and CD4(+) CXCR5(+) FOXP3(\u2212) Tfh-like cells in myasthenia gravis. Neurosci Lett. 2016;630:176\u201382.","DOI":"10.1016\/j.neulet.2016.07.049"},{"key":"2022111412290861367_j_tnsci-2020-0134_ref_007","doi-asserted-by":"crossref","unstructured":"Zhang LJ, Guo HY, Zhang DQ, Wang R, Li T, Li L-M, et al. Analysis of serum interleukin-27 and interleukin-35 concentrations in patients with Guillain-Barre syndrome. Clin Chim Acta. 2017;468:5\u20139.","DOI":"10.1016\/j.cca.2017.02.003"},{"key":"2022111412290861367_j_tnsci-2020-0134_ref_008","doi-asserted-by":"crossref","unstructured":"Meka RR, Venkatesha SH, Dudics S, Acharya B, Moudgil KD. IL-27-induced modulation of autoimmunity and its therapeutic potential. Autoimmun Rev. 2015;14:1131\u201341.","DOI":"10.1016\/j.autrev.2015.08.001"},{"key":"2022111412290861367_j_tnsci-2020-0134_ref_009","doi-asserted-by":"crossref","unstructured":"Cox JH, Kljavin NM, Ramamoorthi N, Diehl L, Batten M, Ghilardi N. IL-27 promotes T cell-dependent colitis through multiple mechanisms. J Exp Med. 2011;208:115\u201323.","DOI":"10.1084\/jem.20100410"},{"key":"2022111412290861367_j_tnsci-2020-0134_ref_010","doi-asserted-by":"crossref","unstructured":"Belle L, Agle K, Zhou V, Yin-Yuan C, Komorowski R, Eastwood D, et al. Blockade of interleukin-27 signaling reduces GVHD in mice by augmenting Treg reconstitution and stabilizing Foxp3 expression. Blood. 2016;128:2068\u201382.","DOI":"10.1182\/blood-2016-02-698241"},{"key":"2022111412290861367_j_tnsci-2020-0134_ref_011","doi-asserted-by":"crossref","unstructured":"Kim G, Shinnakasu R, Saris CJ, Cheroutre H, Kronenberg M. A novel role for IL-27 in mediating the survival of activated mouse CD4 T lymphocytes. J Immunol. 2013;190:1510\u20138.","DOI":"10.4049\/jimmunol.1201017"},{"key":"2022111412290861367_j_tnsci-2020-0134_ref_012","doi-asserted-by":"crossref","unstructured":"Shen H, Xia L, Xiao W, Lu J. Increased levels of interleukin-27 in patients with rheumatoid arthritis. Arthritis Rheum. 2011;63:860\u20131.","DOI":"10.1002\/art.30180"},{"key":"2022111412290861367_j_tnsci-2020-0134_ref_013","doi-asserted-by":"crossref","unstructured":"Wong CK, Chen DP, Tam LS, Li EK, Yin YB, Lam CW. Effects of inflammatory cytokine IL-27 on the activation of fibroblast-like synoviocytes in rheumatoid arthritis. Arthritis Res Ther. 2010;12:R129.","DOI":"10.1186\/ar3067"},{"key":"2022111412290861367_j_tnsci-2020-0134_ref_014","doi-asserted-by":"crossref","unstructured":"Shibata S, Tada Y, Kanda N, Nashiro K, Kamata M, Karakawa M, et al. Possible roles of IL-27 in the pathogenesis of psoriasis. J Invest Dermatol. 2010;130:1034\u20139.","DOI":"10.1038\/jid.2009.349"},{"key":"2022111412290861367_j_tnsci-2020-0134_ref_015","doi-asserted-by":"crossref","unstructured":"Mindur JE, Valenzuela RM, Yadav SK, Boppana S, Dhib-Jalbut S, Ito K. IL-27: a potential biomarker for responders to glatiramer acetate therapy. J Neuroimmunol. 2017;304:21\u20138.","DOI":"10.1016\/j.jneuroim.2016.07.004"},{"key":"2022111412290861367_j_tnsci-2020-0134_ref_016","doi-asserted-by":"crossref","unstructured":"Lalive PH, Kreutzfeldt M, Devergne O, Metz I, Bruck W, Merkler D, et al. Increased interleukin-27 cytokine expression in the central nervous system of multiple sclerosis patients. J Neuroinflamm. 2017;14:144.","DOI":"10.1186\/s12974-017-0919-1"},{"key":"2022111412290861367_j_tnsci-2020-0134_ref_017","doi-asserted-by":"crossref","unstructured":"Do J, Kim D, Kim S, Valentin-Torres A, Dvorina N, Jang E, et al. Treg-specific IL-27Ralpha deletion uncovers a key role for IL-27 in Treg function to control autoimmunity. Proc Natl Acad Sci U S A. 2017;114:10190\u20135.","DOI":"10.1073\/pnas.1703100114"},{"key":"2022111412290861367_j_tnsci-2020-0134_ref_018","doi-asserted-by":"crossref","unstructured":"Do JS, Visperas A, Sanogo YO, Bechtel JJ, Dvorina N, Kim S, et al. An IL-27\/Lag3 axis enhances Foxp3+ regulatory T cell-suppressive function and therapeutic efficacy. Mucosal Immunol. 2016;9:137\u201345.","DOI":"10.1038\/mi.2015.45"},{"key":"2022111412290861367_j_tnsci-2020-0134_ref_019","doi-asserted-by":"crossref","unstructured":"Jeong HN, Lee JH, Suh BC, Choi YC. Serum interleukin-27 expression in patients with myasthenia gravis. J Neuroimmunol. 2015;288:120\u20132.","DOI":"10.1016\/j.jneuroim.2015.09.010"},{"key":"2022111412290861367_j_tnsci-2020-0134_ref_020","doi-asserted-by":"crossref","unstructured":"Marx A, Hohenberger P, Hoffmann H, Pfannschmidt J, Schnabel P, Hofmann H-S, et al. The autoimmune regulator AIRE in thymoma biology: autoimmunity and beyond. J Thorac Oncol. 2010;5:S266\u201372.","DOI":"10.1097\/JTO.0b013e3181f1f63f"},{"key":"2022111412290861367_j_tnsci-2020-0134_ref_021","doi-asserted-by":"crossref","unstructured":"Scarpino S, Di Napoli A, Stoppacciaro A, et al. Expression of autoimmune regulator gene (AIRE) and T regulatory cells in human thymomas. Clin Exp Immunol. 2007;149:504\u201312.","DOI":"10.1111\/j.1365-2249.2007.03442.x"},{"key":"2022111412290861367_j_tnsci-2020-0134_ref_022","doi-asserted-by":"crossref","unstructured":"Thiruppathi M, Rowin J, Ganesh B, Sheng JR, Prabhakar BS, Meriggioli MN. Impaired regulatory function in circulating CD4(+) CD25(high)CD127(low\/\u2212) T cells in patients with myasthenia gravis. Clin Immunol. 2012;145:209\u201323.","DOI":"10.1016\/j.clim.2012.09.012"},{"key":"2022111412290861367_j_tnsci-2020-0134_ref_023","doi-asserted-by":"crossref","unstructured":"Luther C, Adamopoulou E, Stoeckle C, Brucklacher-Waldert V, Rosenkranz D, Stoltze L, et al. Prednisolone treatment induces tolerogenic dendritic cells and a regulatory milieu in myasthenia gravis patients. J Immunol. 2009;183:841\u20138.","DOI":"10.4049\/jimmunol.0802046"},{"key":"2022111412290861367_j_tnsci-2020-0134_ref_024","doi-asserted-by":"crossref","unstructured":"Balandina A, Lecart S, Dartevelle P, Saoudi A, Berrih-Aknin S. Functional defect of regulatory CD4(+) CD25+T cells in the thymus of patients with autoimmune myasthenia gravis. Blood. 2005;105:735\u201341.","DOI":"10.1182\/blood-2003-11-3900"},{"key":"2022111412290861367_j_tnsci-2020-0134_ref_025","doi-asserted-by":"crossref","unstructured":"Li Y, Rauniyar VK, Yin WF, Hu B, Ouyang S, Xiao B, et al. Serum IL-21 levels decrease with glucocorticoid treatment in myasthenia gravis. Neurol Sci. 2014;35:29\u201334.","DOI":"10.1007\/s10072-013-1460-3"},{"key":"2022111412290861367_j_tnsci-2020-0134_ref_026","unstructured":"Hu B, Tian X, Huang H, Jian A, Ouyang S, Yin W, et al. Expression of IL-21 in the peripheral blood of myasthenia gravis patients and its correlation with anti-AChR-Ab class switch. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2010;35:958\u201363."},{"key":"2022111412290861367_j_tnsci-2020-0134_ref_027","doi-asserted-by":"crossref","unstructured":"Gilhus NE. Myasthenia gravis. N Engl J Med. 2016;375:2570\u201381.","DOI":"10.1056\/NEJMra1602678"},{"key":"2022111412290861367_j_tnsci-2020-0134_ref_028","doi-asserted-by":"crossref","unstructured":"Tseng WN, Lo MH, Guo MM, Hsieh KS, Chang WC, Kuo HC. IL-31 associated with coronary artery lesion formation in Kawasaki disease. PLoS One. 2014;9:e105195.","DOI":"10.1371\/journal.pone.0105195"},{"key":"2022111412290861367_j_tnsci-2020-0134_ref_029","doi-asserted-by":"crossref","unstructured":"Maddur MS, Rabin M, Hegde P, Bolgert F, Guy M, Vallat J-M, et al. Intravenous immunoglobulin exerts reciprocal regulation of Th1\/Th17 cells and regulatory T cells in Guillain-Barre syndrome patients. Immunol Res. 2014;60:320\u20139.","DOI":"10.1007\/s12026-014-8580-6"},{"key":"2022111412290861367_j_tnsci-2020-0134_ref_030","doi-asserted-by":"crossref","unstructured":"Kozicky LK, Menzies SC, Hotte N, Madsen KL, Sly LM. Intravenous immunoglobulin (IVIg) or IVIg-treated macrophages reduce DSS-induced colitis by inducing macrophage IL-10 production. Eur J Immunol. 2019;49:1251\u201368.","DOI":"10.1002\/eji.201848014"},{"key":"2022111412290861367_j_tnsci-2020-0134_ref_031","doi-asserted-by":"crossref","unstructured":"Ahmadi M, Aghdam SA, Nouri M, Babaloo Z, Farzadi L, Ghasemzadeh A, et al. Intravenous immunoglobulin (IVIG) treatment modulates peripheral blood Th17 and regulatory T cells in recurrent miscarriage patients: nonrandomized open-label clinical trial. Immunol Lett. 2017;192:12\u20139.","DOI":"10.1016\/j.imlet.2017.10.003"},{"key":"2022111412290861367_j_tnsci-2020-0134_ref_032","doi-asserted-by":"crossref","unstructured":"Galeotti C, Kaveri SV, Bayry J. IVIG-mediated effector functions in autoimmune and inflammatory diseases. Int Immunol. 2017;29:491\u20138.","DOI":"10.1093\/intimm\/dxx039"},{"key":"2022111412290861367_j_tnsci-2020-0134_ref_033","doi-asserted-by":"crossref","unstructured":"Das M, Karnam A, Stephen-Victor E, Gilardin L, Bhatt B, Sharma VK, et al. Intravenous immunoglobulin mediates anti-inflammatory effects in peripheral blood mononuclear cells by inducing autophagy. Cell Death Dis. 2020;11:50.","DOI":"10.1038\/s41419-020-2249-y"},{"key":"2022111412290861367_j_tnsci-2020-0134_ref_034","doi-asserted-by":"crossref","unstructured":"Meka RR, Venkatesha SH, Dudics S, Acharya B, Moudgil KD. IL-27-induced modulation of autoimmunity and its therapeutic potential. Autoimmun Rev. 2015;14:1131\u201341.","DOI":"10.1016\/j.autrev.2015.08.001"},{"key":"2022111412290861367_j_tnsci-2020-0134_ref_035","doi-asserted-by":"crossref","unstructured":"Meka RR, Venkatesha SH, Dudics S, Acharya B, Moudgil KD. IL-27-induced modulation of autoimmunity and its therapeutic potential. Autoimmun Rev. 2015;14:1131\u201341.","DOI":"10.1016\/j.autrev.2015.08.001"}],"container-title":["Translational Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/view\/journals\/tnsci\/11\/1\/article-p302.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/tnsci-2020-0134\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/tnsci-2020-0134\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T12:30:09Z","timestamp":1668429009000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/tnsci-2020-0134\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,1]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,9,9]]},"published-print":{"date-parts":[[2020,9,9]]}},"alternative-id":["10.1515\/tnsci-2020-0134"],"URL":"https:\/\/doi.org\/10.1515\/tnsci-2020-0134","relation":{},"ISSN":["2081-6936"],"issn-type":[{"value":"2081-6936","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,1]]}}}